The Impact of Tofogliflozin on Physiological and Hormonal Function, Serum Electrolytes, and Cardiac Diastolic Function in Elderly Japanese Patients with Type 2 Diabetes Mellitus

The sodium glucose transporter 2 (SGLT2) inhibitor tofogliflozin is a glucose-lowering drug that causes the excretion of surplus glucose by inhibiting SGLT2. Because of tofogliflozin's osmotic diuresis mechanism, patients' serum electrolytes, body fluid levels, and cardiac function must be...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Acta medica Okayama 2022-12, Vol.76 (6), p.705-713
Hauptverfasser:	Higashikawa, Toshihiro, Ito, Tomohiko, Mizuno, Takurou, Ishigami, Keiichiro, Kuroki, Kengo, Maekawa, Naoto, Usuda, Daisuke, Izumida, Toshihide, Yamada, Shinya, Sangen, Ryusho, Hamada, Kazu, Kiyosawa, Jun, Saito, Atsushi, Iguchi, Masaharu, Kasamaki, Yuji, Nakahashi, Takeshi, Fukuda, Akihiro, Saito, Hitoshi, Kanda, Tsugiyasu, Okuro, Masashi
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Blood Glucose Diabetes Mellitus, Type 2 - drug therapy East Asian People Electrolytes - therapeutic use Glycated Hemoglobin Humans Retrospective Studies Sodium-Glucose Transporter 2 - therapeutic use Sodium-Glucose Transporter 2 Inhibitors - pharmacology Sodium-Glucose Transporter 2 Inhibitors - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!